Remeglurant Explained

Remeglurant (; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor.[1] [2] [3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.

See also

Notes and References

  1. International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109 . World Health Organization . . WHO Drug Information . 27 . 2 . 2013 . World Health Organization .
  2. Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V . Merz Pharmaceuticals GmbH . Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators. . US . 7985753 . 4 August 2006 .
  3. Web site: Remeglurant . Adis Insight . Springer Nature Switzerland AG .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Remeglurant".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.